Developer docs
API playgroundTry for free, no card

Search company profiles

Genesis Regenerative

Full company profile

uuid003n69b

Namestring
Genesis Regenerative
Legal namestring
Genesis Regenerative, LLC
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Genesis Regenerative is a privately held US LLC (formed 2023, headquartered in Clearwater, FL with operational offices in Texas) that develops and distributes regenerative medicine products to licensed clinicians. The company's flagship product is the Regenerative Protein Array (RPA), an acellular formulation derived from screened placental tissue that delivers over 300 proteins, cytokines, growth factors, and miRNA, compared with approximately 40 active factors in conventional platelet-rich plasma (PRP) therapies. RPA is manufactured in an FDA-registered facility using a proprietary bioreactor process that harvests components from all three placental germ layers (endo/ecto/mesoderm), positioning the product as a non-biologic alternative to cell-based regenerative treatments.

The company's second product, Push Patch, is a needle-free transdermal peptide delivery system that uses iontophoresis (low-voltage electrodes) to deliver therapeutic molecules through the skin with a 12-hour time-release profile, eliminating the need for injections or IV therapy. Genesis Regenerative sells and licenses these products to clinical practices via a B2B partnership model, providing clinicians with clinical protocols, regulatory support, lab testing, referral marketing assistance, and a secure clinician portal (registry, forum, case study videos, patient financing).

The go-to-market strategy is partnership-driven US clinic expansion. From October 2025 through March 2026, the company rapidly onboarded clinical partners across Florida, Nebraska, Michigan, California, Georgia, Pennsylvania, Hawaii, Nevada, Illinois, and New York, including concierge clinic deployments and specialty practices in podiatry, pain management, functional medicine, and regenerative orthopedics. The Medical Directors Advisory Board (Drs. Jacobson, Johnson, Bregman, Korth) and laboratory leadership (Holly Hewitt, CTBS, 31 years in tissue transplantation) provide clinical and regulatory credibility. Pricing is not publicly disclosed, and the company has not announced any institutional funding rounds, acquisitions, or revenue figures.

Short descriptiontext

Genesis Regenerative is a US regenerative medicine company that distributes its placental-tissue-derived Regenerative Protein Array (RPA) and needle-free Push Patch peptide therapy to licensed clinicians via a B2B clinic partnership model, targeting joint, soft tissue, neurological, and chronic pain conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersClearwater, United States
HQ citystring
Clearwater
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
regenerative medicine, protein array therapy, biologic treatments, needle-free delivery, placental tissue therapy
Industry2 codes
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine Biologics
Social media profiles1 record
Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Regenerative Protein Array (RPA)
Description

The company's primary therapeutic product - an acellular formulation delivering over 300 proteins, cytokines, and growth factors derived from placental tissue.

genesisregenerative.com
+1 more record
Core offering1 text field

Genesis Regenerative develops and distributes two core therapeutic products to licensed clinicians: the Regenerative Protein Array (RPA), an acellular biologic derived from screened placental tissue containing over 300 proteins, cytokines, growth factors, and miRNA; and Push Patch, a needle-free peptide delivery system using iontophoresis technology with 12-hour time-release. The company supports clinicians with clinical, regulatory, administrative, and educational resources to deliver regenerative therapies for joint, soft tissue, neuro-cognitive, podiatric, and peptide-related conditions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Genesis Regenerative offers two core therapeutic products: the Regenerative Protein Array (RPA) as the primary platform product, and Push Patch as a complementary needle-free delivery technology. RPA is an acellular protein formulation derived from placental tissue, while Push Patch enables transdermal peptide delivery through iontophoresis. These products are positioned as next-generation regenerative therapies designed for use by licensed clinicians across multiple medical specialties to address various chronic and acute health conditions.

Product and service2 records
1Regenerative Protein Array (RPA)
CategoryRegenerative Biologic Therapy
Description

An acellular, non-biologic regenerative therapy containing over 300 proteins, cytokines, growth factors, and miRNA derived from screened placental tissue. Produced in an FDA-registered facility using a proprietary bioreactor process that harvests components from all three layers of the placenta (endo/ecto/mesoderm). The product modifies the surrounding cellular environment through biological signals rather than direct cell transformation. Designed for use by licensed clinicians across multiple medical specialties to address joint, soft tissue, musculoskeletal, neuro-cognitive, podiatric, and other chronic and acute conditions.

2Push Patch Needle-Free Peptide Therapy
CategoryDrug Delivery Device
Description

A needle-free peptide delivery system using iontophoresis technology via low voltage electrodes in a patch to deliver therapeutic molecules and peptides through the skin into the bloodstream. Features 12-hour time-release technology providing sustained bioavailability without daily injections or weekly IV treatments. Designed for use by licensed clinicians offering peptide and regenerative therapies to patients seeking non-invasive treatment options.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Organogenesis (NASDAQ: ORGO) markets regenerative biologics including Apligraf, Dermagraft, and PuraPly for wound healing and surgical applications. It is directly comparable to Genesis in selling tissue-derived regenerative products to clinicians for chronic condition management.

TypeBroad incumbent
Description

Arthrex is a large privately-held orthopedic medical device company offering autologous conditioned plasma (ACP) systems, bone graft substitutes, and regenerative biologics. It is a broad incumbent that competes with Genesis for orthopedic clinician relationships at much greater scale.

TypeDirect peer
Description

Surgenex produces placental tissue allografts (e.g., SurForce, SurGraft) sold to orthopedic, wound care, and pain management physicians. It operates in the same regenerative biologic space as Genesis Regenerative.

TypeDirect peer
Description

MIMEDX develops and commercializes placental tissue-based products (EpiFix, AmnioFix, etc.) for wound care and musculoskeletal applications. It is the most direct competitor to Genesis Regenerative's RPA, offering purified tissue-derived biologics to clinicians through a similar specialty distribution model.

TypeDirect peer
Description

Skye Biologics offers a portfolio of dehydrated amniotic membrane and placental tissue allografts for wound, orthopedic, and pain management applications. Its distribution model through specialty physician offices mirrors Genesis Regenerative's clinic-partnership go-to-market approach.

TypeDirect peer
Description

StimLabs produces placental tissue allografts and regenerative biologics (e.g., Stimulen, AmnioMatrix) for wound care and orthopedic use. Like Genesis, it sells processed placental tissue-derived products to specialist clinicians across multiple U.S. states.

TypeBroad incumbent
Description

Vericel (NASDAQ: VCEL) markets MACI (autologous chondrocyte implant) and Epicel for cartilage and burn repair. While it specializes in cell therapies rather than acellular protein arrays, it competes in the orthopedic regenerative medicine category Genesis targets.

TypeBroad incumbent
Description

Integra LifeSciences (NASDAQ: IART) offers regenerative technologies including dermal matrices, wound care, and orthopedic tissue products. It overlaps with Genesis's regenerative biologic positioning as a much larger diversified medical device incumbent.

9Amniox Medical
TypeDirect peer
Description

Amniox Medical (a TissueTech subsidiary) markets CLARIX and NEOX placental tissue products for surgical, orthopedic, and pain management indications. It is a direct competitor in the regenerative protein/biologic category targeted by Genesis's RPA.

TypeEmerging player
Description

BioLab Sciences develops regenerative wound and tissue products including fluidflow and MemoVet amniotic membrane allografts. It is a smaller emerging player overlapping with Genesis's placental tissue-derived biologic positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genesis Regenerative

Regenerative Medicine Biologicsgenesisregenerative.com

Genesis Regenerative is a US regenerative medicine company that distributes its placental-tissue-derived Regenerative Protein Array (RPA) and needle-free Push Patch peptide therapy to licensed clinicians via a B2B clinic partnership model, targeting joint, soft tissue, neurological, and chronic pain conditions.

What Genesis Regenerative does

Genesis Regenerative is a privately held US LLC (formed 2023, headquartered in Clearwater, FL with operational offices in Texas) that develops and distributes regenerative medicine products to licensed clinicians. The company's flagship product is the Regenerative Protein Array (RPA), an acellular formulation derived from screened placental tissue that delivers over 300 proteins, cytokines, growth factors, and miRNA, compared with approximately 40 active factors in conventional platelet-rich plasma (PRP) therapies. RPA is manufactured in an FDA-registered facility using a proprietary bioreactor process that harvests components from all three placental germ layers (endo/ecto/mesoderm), positioning the product as a non-biologic alternative to cell-based regenerative treatments.

The company's second product, Push Patch, is a needle-free transdermal peptide delivery system that uses iontophoresis (low-voltage electrodes) to deliver therapeutic molecules through the skin with a 12-hour time-release profile, eliminating the need for injections or IV therapy. Genesis Regenerative sells and licenses these products to clinical practices via a B2B partnership model, providing clinicians with clinical protocols, regulatory support, lab testing, referral marketing assistance, and a secure clinician portal (registry, forum, case study videos, patient financing).

The go-to-market strategy is partnership-driven US clinic expansion. From October 2025 through March 2026, the company rapidly onboarded clinical partners across Florida, Nebraska, Michigan, California, Georgia, Pennsylvania, Hawaii, Nevada, Illinois, and New York, including concierge clinic deployments and specialty practices in podiatry, pain management, functional medicine, and regenerative orthopedics. The Medical Directors Advisory Board (Drs. Jacobson, Johnson, Bregman, Korth) and laboratory leadership (Holly Hewitt, CTBS, 31 years in tissue transplantation) provide clinical and regulatory credibility. Pricing is not publicly disclosed, and the company has not announced any institutional funding rounds, acquisitions, or revenue figures.

Genesis Regenerative firmographics

Firmographics
Name
Genesis Regenerative
Legal name
Genesis Regenerative, LLC
Website
https://genesisregenerative.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Genesis Regenerative is a US regenerative medicine company that distributes its placental-tissue-derived Regenerative Protein Array (RPA) and needle-free Push Patch peptide therapy to licensed clinicians via a B2B clinic partnership model, targeting joint, soft tissue, neurological, and chronic pain conditions.
Ownership category
akta.pro rank

Genesis Regenerative industry classification

Industry
Product category
Regenerative Medicine Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Regenerative medicine
  • Protein array therapy
  • Biologic treatments
  • Needle-free delivery
  • Placental tissue therapy

Where Genesis Regenerative is headquartered

Location

Headquarters

HQ city
Clearwater
HQ country
United States
HQ region
North America

Markets served

Genesis Regenerative business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Genesis Regenerative product offering

Product offering

Core offering

Genesis Regenerative develops and distributes two core therapeutic products to licensed clinicians: the Regenerative Protein Array (RPA), an acellular biologic derived from screened placental tissue containing over 300 proteins, cytokines, growth factors, and miRNA; and Push Patch, a needle-free peptide delivery system using iontophoresis technology with 12-hour time-release. The company supports clinicians with clinical, regulatory, administrative, and educational resources to deliver regenerative therapies for joint, soft tissue, neuro-cognitive, podiatric, and peptide-related conditions.

Product overview

Genesis Regenerative offers two core therapeutic products: the Regenerative Protein Array (RPA) as the primary platform product, and Push Patch as a complementary needle-free delivery technology. RPA is an acellular protein formulation derived from placental tissue, while Push Patch enables transdermal peptide delivery through iontophoresis. These products are positioned as next-generation regenerative therapies designed for use by licensed clinicians across multiple medical specialties to address various chronic and acute health conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • Regenerative Protein Array (RPA): The company's primary therapeutic product - an acellular formulation delivering over 300 proteins, cytokines, and growth factors derived from placental tissue.
  • Push Patch

Products and services

  • Regenerative Protein Array (RPA) An acellular, non-biologic regenerative therapy containing over 300 proteins, cytokines, growth factors, and miRNA derived from screened placental tissue. Produced in an FDA-registered facility using a proprietary bioreactor process that harvests components from all three layers of the placenta (endo/ecto/mesoderm). The product modifies the surrounding cellular environment through biological signals rather than direct cell transformation. Designed for use by licensed clinicians across multiple medical specialties to address joint, soft tissue, musculoskeletal, neuro-cognitive, podiatric, and other chronic and acute conditions.
  • Push Patch Needle-Free Peptide Therapy A needle-free peptide delivery system using iontophoresis technology via low voltage electrodes in a patch to deliver therapeutic molecules and peptides through the skin into the bloodstream. Features 12-hour time-release technology providing sustained bioavailability without daily injections or weekly IV treatments. Designed for use by licensed clinicians offering peptide and regenerative therapies to patients seeking non-invasive treatment options.

Companies that use Genesis Regenerative

Customer profile

Ideal customer profiles2 records

Genesis Regenerative technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Genesis Regenerative partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

Genesis Regenerative competitors and assessment

Company assessment

Direct peers

  • Organogenesis: Organogenesis (NASDAQ: ORGO) markets regenerative biologics including Apligraf, Dermagraft, and PuraPly for wound healing and surgical applications. It is directly comparable to Genesis in selling tissue-derived regenerative products to clinicians for chronic condition management.
  • Surgenex: Surgenex produces placental tissue allografts (e.g., SurForce, SurGraft) sold to orthopedic, wound care, and pain management physicians. It operates in the same regenerative biologic space as Genesis Regenerative.
  • MIMEDX: MIMEDX develops and commercializes placental tissue-based products (EpiFix, AmnioFix, etc.) for wound care and musculoskeletal applications. It is the most direct competitor to Genesis Regenerative's RPA, offering purified tissue-derived biologics to clinicians through a similar specialty distribution model.
  • Skye Biologics: Skye Biologics offers a portfolio of dehydrated amniotic membrane and placental tissue allografts for wound, orthopedic, and pain management applications. Its distribution model through specialty physician offices mirrors Genesis Regenerative's clinic-partnership go-to-market approach.
  • StimLabs: StimLabs produces placental tissue allografts and regenerative biologics (e.g., Stimulen, AmnioMatrix) for wound care and orthopedic use. Like Genesis, it sells processed placental tissue-derived products to specialist clinicians across multiple U.S. states.
  • Amniox Medical: Amniox Medical (a TissueTech subsidiary) markets CLARIX and NEOX placental tissue products for surgical, orthopedic, and pain management indications. It is a direct competitor in the regenerative protein/biologic category targeted by Genesis's RPA.

Broad incumbents

  • Arthrex: Arthrex is a large privately-held orthopedic medical device company offering autologous conditioned plasma (ACP) systems, bone graft substitutes, and regenerative biologics. It is a broad incumbent that competes with Genesis for orthopedic clinician relationships at much greater scale.
  • Vericel: Vericel (NASDAQ: VCEL) markets MACI (autologous chondrocyte implant) and Epicel for cartilage and burn repair. While it specializes in cell therapies rather than acellular protein arrays, it competes in the orthopedic regenerative medicine category Genesis targets.
  • Integra LifeSciences: Integra LifeSciences (NASDAQ: IART) offers regenerative technologies including dermal matrices, wound care, and orthopedic tissue products. It overlaps with Genesis's regenerative biologic positioning as a much larger diversified medical device incumbent.

Emerging players

  • BioLab Sciences: BioLab Sciences develops regenerative wound and tissue products including fluidflow and MemoVet amniotic membrane allografts. It is a smaller emerging player overlapping with Genesis's placental tissue-derived biologic positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Genesis Regenerative social profiles

Digital presence

Genesis Regenerative financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genesis Regenerative leadership team

Management profile

Number of profiles

Profiles5 records

Genesis Regenerative funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genesis Regenerative M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesis Regenerative

What does Genesis Regenerative do?

Genesis Regenerative develops and distributes two core therapeutic products to licensed clinicians: the Regenerative Protein Array (RPA), an acellular biologic derived from screened placental tissue containing over 300 proteins, cytokines, growth factors, and miRNA; and Push Patch, a needle-free peptide delivery system using iontophoresis technology with 12-hour time-release. The company supports clinicians with clinical, regulatory, administrative, and educational resources to deliver regenerative therapies for joint, soft tissue, neuro-cognitive, podiatric, and peptide-related conditions.

Is Genesis Regenerative a public or private company?

Genesis Regenerative is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Genesis Regenerative founded?

Genesis Regenerative was founded in 2023. It employs 1 to 10 people.

Where is Genesis Regenerative based?

Genesis Regenerative is headquartered in Clearwater, United States, in the North America region.

Who are Genesis Regenerative's main competitors?

Direct peers on record are Organogenesis, Surgenex, MIMEDX, Skye Biologics, StimLabs and Amniox Medical. Broad incumbents are Arthrex, Vericel and Integra LifeSciences. BioLab Sciences is listed as an emerging player.

Does Genesis Regenerative have an API?

No public API is recorded for Genesis Regenerative.

What industry is Genesis Regenerative in?

Genesis Regenerative's product category is Regenerative Medicine Biologics. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireGenesis Regenerative Challenges Clinicians to Ask 'What’s In Your Vial?' & Empowers Patients to Become Smarter ConsumersGenesis Regenerative launched two educational campaigns to promote transparency in regenerative medicine, asking clinicians to examine product composition and patients to ask informed questions. The campaigns emphasize independent testing, specific protein concentrations, and FDA establishment registration, and include a Zoom discussion on November 18, 2026.EIN PresswireGenesis Regenerative Challenges Clinicians to Ask 'What’s In Your Vial?' & Empowers Patients to Become Smarter ConsumersGenesis Regenerative launched two educational campaigns to promote transparency in regenerative medicine, targeting clinicians and patients. The campaigns emphasize independent testing, specific protein concentrations, and FDA registration, and include a Zoom discussion on November 18, 2026.EIN PresswireDr. Jennifer Sartori Brings the Genesis Regenerative Protein Array to New Hampshire for the First TimeDr. Jennifer Sartori of Northeast Foot and Ankle added the Genesis Regenerative Protein Array (RPA) to her practice in Portsmouth and Nashua, New Hampshire. The practice becomes the first in the state to offer RPA, which is part of the Genesis Roadmap to Health. The company launched the Roadmap in August.EIN PresswireHOCATT® and Genesis Regenerative Announce Strategic PartnershipHOCATT and Genesis Regenerative announced a strategic partnership, making Genesis's Regenerative Protein Array and Roadmap to Health available through HOCATT for qualified medical practitioners. The partnership combines HOCATT's multi-technology wellness platform with Genesis's regenerative products, with a keynote presentation on October 7, 2026.EIN PresswireGenesis Regenerative Launches the Roadmap to Health, Pairing Genomic Testing With Regenerative Proteins and PeptidesGenesis Regenerative launched the Roadmap to Health, combining genomic testing, regenerative proteins, and peptide patches into a three-stage protocol. The stages are Assess, Repair, and Maintain, with the company's medical leadership citing improved clinical outcomes. The roadmap is now available to clinicians across the Genesis network.EIN PresswireGenesis Regenerative’s New Advisory Board Member Dr. Hasnain Haider-Shah Featured on Cover of Global Healthcare MagazineDr. Hasnain Haider-Shah, a neurointerventional surgeon and Genesis Regenerative advisory board member, is featured on the cover of Global Healthcare Magazine's July 2026 issue. The profile highlights his work in neurorestoration and his first transcarotid aneurysm procedure in the UAE. He also serves on Genesis Regenerative's Clinical Advisory Board.EIN PresswireGenesis Regenerative Names Columbus Ophthalmologist & Health-Span Clinics' Dr. Aaron C. Mack to Clinical Advisory BoardDr. Aaron C. Mack, founder of Health-Span Clinics, was appointed to Genesis Regenerative's Clinical Advisory Board and introduced the Regenerative Protein Array (RPA) to his Columbus, Ohio practice. RPA is a cell-free matrix with over 300 cytokines, delivered via IV or intrathecal injection, and is paired with modalities like HBOT and photobiomodulation.EIN PresswireMinnesota Orthopedic Spine Surgeon Incorporates Acellular Protein Arrays Alongside New Book ReleaseHyperCharge Health in Edina, Minnesota, integrated Genesis Regenerative's Regenerative Protein Array (RPA) alongside Dr. Stefano Sinicropi's new book 'Wellness at the Speed of Light.' The acellular protein array contains over 300 proteins and is applied in 10 minutes without cellular extraction. The clinic pairs it with integrative therapies like peptide and IV treatments.EIN PresswireMaster Interventional Instructor Integrates Genesis Regenerative's RPA to 'Prepare the Soil' to Support Targeted HealingHyperCharge Health's Institute for Regenerative Medicine in Edina, MN, has integrated Genesis Regenerative's Regenerative Protein Array (RPA) into its care protocol. The acellular, non-DNA array delivers over 300 signaling proteins to prepare the body's internal environment before targeted interventions. The clinic also offers advanced imaging guidance and accepts specialized payment options.EIN PresswireEthos Wellness Center Becomes First Clinic in Oklahoma City to Integrate Genesis Regenerative’s Protein Array TechnologyEthos Wellness Center, opened December 15, 2025, became the first Oklahoma City clinic to integrate Genesis Regenerative's Regenerative Protein Array (RPA). The acellular, non-DNA array contains over 300 cytokines and growth factors, administered via neuraxial delivery for neuro-wellness. The clinic offers outpatient sessions in 15-30 minutes.